BMS-791826

BMS-791826 is an investigational small molecule drug developed by Bristol Myers Squibb. It is an azaxanthene-based selective glucocorticoid receptor partial agonist designed for the treatment of immunological and inflammatory diseases. The compound demonstrates high affinity binding to the glucocorticoid receptor (GR), with potent transrepression of proinflammatory transcription factors such as AP‑1 and NF‑κB and reduced transactivation compared to classical glucocorticoids like prednisolone. This profile suggests anti-inflammatory activity with potentially fewer side effects associated with full GR agonists. BMS‑791826 has been evaluated in preclinical models and a completed phase 1 clinical trial assessing its pharmacokinetics and pharmacodynamics in healthy males[1][2][3][4][5][6].

Other names

60BN6CDL0KUNII-60BN6CDL0KUNII60BN6CDL0KUNII 60BN6CDL0K1008116-73-15H-(1)Benzopyrano(2,3-b)pyridine-5-acetamide, 2-(4-((ethylmethylamino)carbonyl)-3-fluorophenyl)-alpha,alpha-dimethyl-N-1,3,4-thiadiazol-2-yl-, (5S)-